Sign in to view content

Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD

Carl C. Awh, MD, FASRS

Video
Published 2021

Related

Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2018
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab: From PRN Refills in Phase 2 Ladder to Fixed 24-Week Refills In Phase 3 Archway
Dilsher S. Dhoot, MD
Annual Meeting Talks
2020
Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab (PDS)
Jordan M. Graff, MD, FACS
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more